Business Wire

CA-AGENDIA

10.12.2021 00:02:04 CET | Business Wire | Press release

Share
Analysis Presented at SABCS 2021 Confirms MammaPrint® and BluePrint® Predict Outcomes Following Neoadjuvant Chemotherapy

Agendia, Inc. , a world leader in precision oncology for breast cancer, today shared data demonstrating the ability of MammaPrint® and BluePrint® to predict patient outcomes following neoadjuvant chemotherapy (NAC) at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021).

The poster, titled MammaPrint and BluePrint are prognostic of outcome following neoadjuvant chemotherapy , presents findings that indicate MammaPrint and BluePrint accurately correlated with chemosensitivity and outcomes in NAC-treated patients. The research was conducted in collaboration with Cedars-Sinai Medical Center.

Notably, approximately 1 in 4 tumors which were MammaPrint High Risk (Luminal B) prior to NAC became MammaPrint Low Risk (Luminal A) when the post-treatment tissue was analyzed. Patients with reclassified MammaPrint Low Risk tumors had improved five-year outcomes compared to patients that remained High Risk after treatment. These data signal a role for serial genomic testing to determine proper classification of breast cancer tumors following NAC treatment in order to appropriately manage a woman’s future treatment plan and prognosis.

“By analyzing MammaPrint and BluePrint on pre- and post-NAC tissue samples for those with residual disease, we unlock new insights about their clinical utility and potential impact on treatment decisions given the biological changes that may occur following initial intervention,” said Alice P. Chung, MD, Division of Surgical Oncology, Department of Surgery, Cedars-Sinai Medical Center. “The importance of accurate genomic classification of a tumor is crucial, especially in the context of these findings where 1 in 4 High Risk tumors became Low Risk – insights which can significantly affect our treatment planning discussions with patients.”

The analysis presented at SABCS 2021 features data from 128 women (median age 50) with stage I-III early breast cancer (EBC), of any clinical subtype, diagnosed from 2007-2016 who received NAC at Cedars-Sinai Medical Center. Among 111 pre-treated tumors, MammaPrint High Risk tumors had a significantly higher pathological complete response (pCR) rate than Low Risk tumors. Amongst tumors that had discordant MammaPrint results between pre- and post-treatment samples, the only change observed was from High Risk to Low Risk. BluePrint results were very consistent between pre- and post-NAC samples (92% concordance) with reclassification only occurring in the HER2-Type cohort, consistent with the known heterogeneity in clinically HER2-positive tumors.

“Neoadjuvant chemotherapy is the standard of care for the initial treatment of certain types of breast cancer, and for many women, the clinical response to therapy is thought to carry prognostic implications. This study illustrates the additional information provided by our genomic assays regarding response to therapy and prognosis,” said William Audeh, MD, Chief Medical Officer at Agendia and a study author. “While changes in the MammaPrint Risk index with treatment are clearly associated with outcome, it is also important to note the consistency of BluePrint results pre- and post- treatment with neoadjuvant chemotherapy. These data further demonstrate the prognostic accuracy of the assays and confirm the importance of genomic information in our quest to identify better biomarkers in patients treated with neoadjuvant chemotherapy.”

Future studies will study the effect of NAC on the breast cancer transcriptome and its association with clinical outcomes.

About Agendia

Agendia is a mission-driven company focused on enabling optimized treatment planning by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes and quality of life for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.

MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.

For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns18.11.2026 09:01:00 CET | Press release

Organizations with embedded network resilience report outage costs $6 million lower, Opengear research finds Nearly three in four organizations (72%) have delayed, scaled back or paused an AI or edge project in the past 12 months over concerns about network resilience, according to new research from Opengear, a Digi International company (NASDAQ: DGII) (www.digi.com). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118888190/en/ 72% of Organizations Have Delayed, Scaled Back or Paused AI and Edge Projects Over Resilience Concerns The same research shows how the best-prepared organizations fare. Organizations with embedded network resilience, meaning they can reach and recover critical infrastructure when the primary network is down, reported estimated average outage costs $6 million lower over the past 12 months than organizations with less developed resilience capabilities ($12.4 million versus $18.8 million). The advanta

SWISSto12 Selects DLR GSOC as Flight Dynamics Software Partner to Support Upcoming HummingSat Satellite Missions18.11.2026 09:00:00 CET | Press release

Agreement underscores SWISSto12’s expanding relationship with key players in Germany’s space ecosystem SWISSto12, one of the world’s fastest-growing satellite and aerospace companies, today announced it has contracted the German Aerospace Center (DLR) to serve as the company’s primary flight dynamics software provider across its upcoming HummingSat GEO satellite missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118073472/en/ SWISSto12 has selected DLR’s GSOC as its primary flight dynamics software provider for upcoming HummingSat GEO satellite missions. Under this agreement, GSOC will deliver capabilities that span orbit determination, propagation, manoeuvre planning and calibration, orbit events, antenna pointing, and long-term mission analysis. The collaboration is designed to standardise flight dynamics across SWISSto12 programmes, using a heritage European solution integrated into the company’s ground segment a

Abbove Brings European Wealth Planning Into the AI Era18.11.2026 08:05:00 CET | Press release

With the new Abbove MCP connector, advisors can now securely connect their AI tools to their clients’wealth data held in Abbove. Abbove, the European wealth planning platform used by more than 1,450 advisors serving more than 40,000 families across Europe, today launched its MCP connector. Through the open Model Context Protocol, advisors can put their clients’ complete wealth picture to work in the AI tools their institution has chosen, such as Claude, ChatGPT, Mistral or Copilot, within their access rights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117076275/en/ One question, your whole client book: your AI tool reads Abbove and shows which clients have cash coming free in the next 12 months, with dates and amounts. The difference lies in the data.AI tools are only as good as the data they consume. Abbove builds on its ability to model each family’s wealth data in a complete and structured way. Co-built by advisors

Wolters Kluwer’s Future Ready Accountant report: Redesigning work around AI is the next competitive advantage18.11.2026 06:00:00 CET | Press release

The AI adoption race is giving way to a bigger divide: firms that redesign work and those that fall behind Wolters Kluwer Tax & Accounting today released the third edition of its Future Ready Accountant report, revealing a profession operating from a position of strength but at a turning point. Based on responses from more than 2,600 accounting professionals worldwide, the report finds firms are growing, confident, and widely adopting AI. However, few have redesigned how information, workflows, and professional expertise work together. The report shows that this transformation is what will turn today’s growth into lasting value. “Adopting AI is only the first step. The real advantage comes from connecting it to how the whole firm works,” said Jason Marx, CEO, Wolters Kluwer Tax & Accounting. “This year’s Future Ready Accountant report shows the firms that pull ahead will be the ones that rethink their workflows and give their people more room to create value for clients.” The global re

Visa Expands Agentic Ready to Help Scale Trusted AI Commerce Globally18.11.2026 05:30:00 CET | Press release

Adyen, Antom, Billtrust, Checkout.com, Fiserv, Global Payments, PayPal, Stripe along with over 140 initial participants join Agentic Ready program for acceptance ecosystem.Merchants, B2B suppliers, payment providers, acquirers and commerce platforms can now join the 175+ issuers already participating in Agentic Ready across 45 markets. Visa (NYSE: V), a world leader in digital payments, today announced the expansion of the Visa Agentic Ready program to the acceptance ecosystem. As a part of Visa Intelligent Commerce, the expanded program helps merchants, payment service providers (PSPs), and acquirers prepare for agent-initiated transactions and participate in the next era of commerce. The program is launching with more than 140 participants, with additional financial institutions, merchants and enablers expected to join throughout 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117269823/en/ "Agentic commerce is alr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye